Soluble Guanylyl Cyclase
-
Subject Areas on Research
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
- A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase.
- Biochemistry of soluble guanylate cyclase.
- Biomarkers in Pulmonary Vascular Disease: Gauging Response to Therapy.
- Conformationally distinct five-coordinate heme-NO complexes of soluble guanylate cyclase elucidated by multifrequency electron paramagnetic resonance (EPR).
- Dissociation of nitric oxide from soluble guanylate cyclase and heme-nitric oxide/oxygen binding domain constructs.
- Effect of the isoflavone genistein against galactose-induced cataracts in rats.
- Exploring New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Direction?
- Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention.
- Heme-assisted S-nitrosation desensitizes ferric soluble guanylate cyclase to nitric oxide.
- Incorporation of tyrosine and glutamine residues into the soluble guanylate cyclase heme distal pocket alters NO and O2 binding.
- Mechanisms and Models in Heart Failure: A Translational Approach.
- Nucleotide regulation of soluble guanylate cyclase substrate specificity.
- Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
- Probing domain interactions in soluble guanylate cyclase.
- Probing soluble guanylate cyclase activation by CO and YC-1 using resonance Raman spectroscopy.
- Soluble guanylate cyclase is activated differently by excess NO and by YC-1: resonance Raman spectroscopic evidence.
- Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
- Soluble guanylate cyclase: a potential therapeutic target for heart failure.
- Structure and regulation of soluble guanylate cyclase.
- Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.